Gastric Cancer Risk in Patients with Long-Term Use of Proton Pump Inhibitors: A Systematic Review and Meta-Analysis of Observational and Interventional Studies

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2023 Jul 11

PMID 37432532

Authors

Sharon Pan

Aaron P Thrift

Ghida Akhdar

Hashem B El-Serag

Affiliations

Soon will be listed here.

Abstract

Background: A growing number of studies that differ in design, quality, and results report an association between the use of proton pump inhibitors (PPIs) and the risk of gastric cancer (GC). We conducted a systematic review and meta-analysis, when possible, of observational and interventional studies examining PPI use and risk of GC.

Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We identified studies fully published in English through January 2023 using MeSH and non-MeSH keywords. We used random effects models to calculate pooled risk estimates with 95% confidence interval (CI) between PPI use and overall GC, cardia GC, and non-cardia GC. We estimated heterogeneity (I) among studies. We examined the effect of study design and quality, GC site, H. pylori infection, and PPI duration. We assessed quality using the Newcastle-Ottawa Quality Assessment Scale and Risk Of Bias In Non-randomized Studies of Interventions.

Results: We identified 15 observational studies, of which 13 were included in the meta-analysis (six cohort and seven case-control). There was a modest 1.67-fold increase in overall GC risk (95% CI 1.39, 2.00) and no increase in cardia GC risk [odds ratio (OR) 1.12; 95% CI 0.80, 1.56] with PPI use. However, there was high heterogeneity (I = 61.3%, p = 0.004) among studies. All but one study had at least moderate risk of bias. In the six studies accounting for H. pylori, GC risk associated with PPI use increased slightly (OR 1.78; 95% CI 1.25, 2.52). Duration response was not reported consistently to allow pooled estimates. We identified only one interventional randomized controlled study that included GC as an outcome of interest, and it did not show increased GC risk.

Conclusions: The overall available evidence is not supportive of a meaningful change in GC risk, either cardia or non-cardia, with PPI use.

Citing Articles

Proton Pump Inhibitors and Oral-Gut Microbiota: From Mechanism to Clinical Significance.

Zhang X, Li Q, Xia S, He Y, Liu Y, Yang J Biomedicines. 2024; 12(10).

PMID: 39457584 PMC: 11504961. DOI: 10.3390/biomedicines12102271.

References

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Peng Y, Huang L, Lin C, Hsu W, Chang C, Yeh H . Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD. Gut. 2018; 68(2):374-376. DOI: 10.1136/gutjnl-2018-316057. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Cheung K, Leung W . Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019; 12:1756284819834511. PMC: 6415482. DOI: 10.1177/1756284819834511. View

Lai S, Lai H, Lin C, Liao K . Proton pump inhibitors and risk of gastric cancer in a case-control study. Gut. 2018; 68(4):765-767. DOI: 10.1136/gutjnl-2018-316371. View

Seo S, Park C, Chan You S, Kim J, Lee K, Kim J . Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut. 2021; 70(11):2066-2075. DOI: 10.1136/gutjnl-2020-323845. View

Brusselaers N, Lagergren J, Engstrand L . Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol. 2019; 62:101585. DOI: 10.1016/j.canep.2019.101585. View

Segna D, Brusselaers N, Glaus D, Krupka N, Misselwitz B . Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis. Therap Adv Gastroenterol. 2021; 14:17562848211051463. PMC: 8586163. DOI: 10.1177/17562848211051463. View

Johnson D, Benjamin S, Vakil N, Goldstein J, Lamet M, Whipple J . Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001; 96(1):27-34. DOI: 10.1111/j.1572-0241.2001.03443.x. View

10.

Gough A, Long R, Cooper B, Fosters C, Garrett A, Langworthy C . Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1996; 10(4):529-39. DOI: 10.1046/j.1365-2036.1996.14156000.x. View

11.

Fiocca R, Mastracci L, Attwood S, Ell C, Galmiche J, Hatlebakk J . Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther. 2012; 36(10):959-71. DOI: 10.1111/apt.12052. View

12.

Howden C, Larsen L, Perez M, Palmer R, Atkinson S . Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther. 2009; 30(9):895-907. DOI: 10.1111/j.1365-2036.2009.04119.x. View

13.

Brusselaers N, Wahlin K, Engstrand L, Lagergren J . Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017; 7(10):e017739. PMC: 5665226. DOI: 10.1136/bmjopen-2017-017739. View

14.

Lee J, Merchant S, Schneider J, Jensen C, Fireman B, Quesenberry C . Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. Am J Gastroenterol. 2020; 115(5):706-715. DOI: 10.14309/ajg.0000000000000591. View

15.

Ng A, Ng P, Ip A, Cheung K, Siu C . Association between proton pump inhibitors after percutaneous coronary intervention and risk of gastric cancer. BMJ Open Gastroenterol. 2021; 8(1). PMC: 8359470. DOI: 10.1136/bmjgast-2021-000719. View

16.

Peng T, Wu T, Li C . Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2022; 28(1):99-109. DOI: 10.1007/s10147-022-02253-2. View

17.

Moayyedi P, Eikelboom J, Bosch J, Connolly S, Dyal L, Shestakovska O . Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019; 157(3):682-691.e2. DOI: 10.1053/j.gastro.2019.05.056. View

18.

Thrift A, Wenker T, El-Serag H . Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023; 20(5):338-349. DOI: 10.1038/s41571-023-00747-0. View

19.

Niikura R, Hayakawa Y, Hirata Y, Yamada A, Fujishiro M, Koike K . Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for : a retrospective cohort analysis. Gut. 2017; 67(10):1908-1910. DOI: 10.1136/gutjnl-2017-315710. View

20.

Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View